A recently published study in Clinical Infectious Diseases shows that Avelox® (moxifloxacin HCl) monotherapy is as powerful as a high dose combination regimen of ceftriaxon plus levofloxacin in the treatment of hospitalised patients with community-acquired pneumonia (CAP). A total of 569 patients at 69 centres in 17 countries from Southern and Northern Europe, Latin America and South Africa were treated in the MOTIV(1) trial (MOxifloxacin Treatment IV).

More: continued here

This entry was posted on Thursday, May 22nd, 2008 at 10:05 am and is filed under Infectious Diseases / Bacteria / Viruses. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.